Camp4 Therapeutics Corp 8-K

What Happened
On May 14, 2026, Camp4 Therapeutics Corporation (CAMP) announced new preclinical data showing its investigational candidate CMP-002 improved seizure threshold and reduced seizure severity in a model of SYNGAP1‑Related Disorder. The company issued a press release and updated its corporate slide presentation under Regulation FD; both materials were furnished as exhibits to the Form 8‑K.

Key Details

• Filing date: May 14, 2026 (Form 8‑K, Item 7.01 Regulation FD Disclosure).
• Materials furnished: Exhibit 99.1 — press release titled “CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP‑002 Improves Seizure Threshold and Severity in a Model of SYNGAP1‑Related Disorder”; Exhibit 99.2 — updated corporate slide presentation (dated May 2026).
• Signature: Report signed by Josh Mandel‑Brehm, President and CEO, dated May 14, 2026.
• Nature of data: Preclinical (animal/model) results reporting improvements in seizure threshold and severity; no clinical data or financial results were disclosed in this filing.

Why It Matters
These disclosed preclinical results signal scientific progress for CMP‑002 in a genetically defined neurodevelopmental disorder (SYNGAP1), which could influence investor awareness and interest in Camp4’s pipeline. However, the findings are preclinical — not clinical — so any potential commercial or regulatory implications depend on future clinical development and trial outcomes. The filing contains informational materials (press release and slides) rather than operational or financial changes.